Anti‐ LINGO ‐1 treatment restores myelination of corticospinal tract neurons and improves functional recovery after stroke
Brain Pathology · 2025-01 · 35 (1)
DOI: 10.1111/bpa.13280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Pathology, online erschienen am 30.06.2024. Verfasst von Jan-Kolja Strecker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany. Hauptthemen laut MEDLINE: Recovery of Function, Pyramidal Tracts, Myelin Sheath, Stroke. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Demyelination of corticospinal tract neurons contributes to long‐term disability after cortical stroke. Nonetheless, poststroke myelin loss has not been addressed as a therapeutic target, so far. We hypothesized that an antibody‐mediated inhibition of the Nogo receptor‐interacting protein (LINGO‐1, leucine‐rich repeat and immunoglobulin domain‐containing Nogo receptor‐interacting protein) may counteract myelin loss, enhance remyelination and axonal growth, and thus promote functional recovery following stroke. To verify this hypothesis, mice were subjected to photothrombotic stroke and received either an antibody against LINGO‐1 ( n = 19) or a control treatment ( n = 18). Behavioral tests were performed to assess the effects of anti‐LINGO‐1 treatment on the functional recovery. Seven weeks after stroke, immunohistochemical analyses were performed to analyze the effect of anti‐LINGO‐1 treatment on myelination and axonal loss of corticospinal tract neurons, proliferation of oligodendrocytes and neurogenesis. Anti‐LINGO‐1 treatment resulted in significantly improved functional recovery ( p < 0.0001, repeated measures analysis of variance), and increased neurogenesis in the hippocampus and subventricular zone of the ipsilateral hemisphere ( p = 0.0094 and p = 0.032, t ‐test). Notably, we observed a significant increase in myelin ( p = 0.0295, t ‐test), platelet‐derived growth factor receptor α‐positive oligodendrocyte precursor cells ( p = 0.0356, t ‐test) and myelinating adenomatous polyposis coli‐positive cells within the ipsilateral internal capsule of anti‐LINGO‐1‐treated mice ( p = 0.0021, t ‐test). In conclusion, we identified anti‐LINGO‐1 as the first neuroregenerative treatment that counteracts poststroke demyelination of corticospinal tract neurons, presumably by increased proliferation of myelin precursor cells, and thereby improves functional recovery. Most importantly, our study presents myelin loss as a novel therapeutic target following stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.
ORCID-Profile: Antje Schmidt-Pogoda
Zitieren
APA
Strecker, J. K., Schmidt-Pogoda, A., Diederich, K., Zaremba, D., Wieters, F., Beuker, C., Koecke, M. H. M., Straeten, F. A., Wiendl, H., & Minnerup, J. (2025). Anti‐ LINGO ‐1 treatment restores myelination of corticospinal tract neurons and improves functional recovery after stroke. Brain Pathology, 35(1). https://doi.org/10.1111/bpa.13280
Vancouver
Strecker JK, Schmidt-Pogoda A, Diederich K, Zaremba D, Wieters F, Beuker C, et al. Anti‐ LINGO ‐1 treatment restores myelination of corticospinal tract neurons and improves functional recovery after stroke. Brain Pathology. 2025;35(1). doi:10.1111/bpa.13280
BibTeX
@article{Strecker2025,
author = {Strecker, Jan-Kolja and Schmidt-Pogoda, Antje and Diederich, Kai and Zaremba, Dario and Wieters, Frederique and Beuker, Carolin and Koecke, Mailin Hannah Marie and Straeten, Frederike Anne and Wiendl, Heinz and Minnerup, Jens},
title = {Anti‐ LINGO ‐1 treatment restores myelination of corticospinal tract neurons and improves functional recovery after stroke},
journal = {Brain Pathology},
year = {2025},
volume = {35},
number = {1},
doi = {10.1111/bpa.13280}
}
EUVIMED